Surrozen (SRZN) Income from Continuing Operations (2020 - 2026)
Surrozen (SRZN) recorded quarterly Income from Continuing Operations of 9544000.0 in Q1 2026, up 19.47% quarter-over-quarter from 11851000.0 in Q4 2025, and down 3.12% on a YoY basis from 9851630.6 in Q1 2025.
Surrozen (SRZN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Surrozen's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 9544000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 3.12% year-over-year to 9544000.0; the TTM figure through Mar 2026 stood at 39361000.0 (down 61.61% YoY), while the FY2025 annual figure was 39072000.0, down 63.85% from the prior year.
- Income from Continuing Operations was 9544000.0 for Q1 2026 at Surrozen, up from 11851000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1663000.0 in Q3 2024 to a low of 14444000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 9380000.0 across 5 years, with a median of 9544000.0 in 2026.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 115.8% in 2024, then plunged 699.76% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 1695000.0 in 2022, then plunged by 443.66% to 9215000.0 in 2023, then climbed by 10.96% to 8205000.0 in 2024, then slumped by 44.44% to 11851000.0 in 2025, then grew by 19.47% to 9544000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 9544000.0 (Q1 2026), 11851000.0 (Q4 2025), and 9974000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -9.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.54 Mn |
| Dec 31, 2025 | -11.85 Mn |
| Sep 30, 2025 | -9.97 Mn |
| Jun 30, 2025 | -7.99 Mn |
| Mar 31, 2025 | -9.26 Mn |
| Dec 31, 2024 | -8.21 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | -8.56 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -9.22 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -9.65 Mn |
| Mar 31, 2023 | -14.05 Mn |
| Dec 31, 2022 | -1.70 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -14.01 Mn |
| Mar 31, 2022 | -14.44 Mn |
| Dec 31, 2021 | -14.95 Mn |
| Sep 30, 2021 | -13.69 Mn |
| Jun 30, 2021 | -12.65 Mn |